Loading organizations...
§ Private Profile · Montréal, QC, Canada
Biopharmaceutical company developing novel drugs for gastrointestinal disorders, leveraging expertise in preclinical and clinical development.
Based in Montreal, Quebec, gIcare Pharma is a clinical-stage biopharmaceutical company that researches and develops novel therapeutic drugs specifically targeting a wide range of complex gastrointestinal disorders. The enterprise concentrates its research efforts entirely within the specialized gastroenterology sector, utilizing its internal scientific expertise to advance targeted drug candidates through rigorous preclinical and clinical development phases. Operating as a privately held, venture-backed entity, the firm has successfully secured institutional financial backing to fund its pipeline from prominent life sciences investors, including Genesys Capital Management and Forbion. The organization's clinical development programs and strategic initiatives have been guided by pharmaceutical industry veterans such as Patrick Colin. Colin previously accumulated over thirty-five years of specialized drug development experience at major multinational healthcare corporations like Bristol-Myers Squibb. gIcare Pharma was officially established as an independent biotechnology venture in 2011.
gIcare Pharma has raised $7.1M across 1 funding round.
gIcare Pharma has raised $7.1M in total across 1 funding round.
gIcare Pharma has raised $7.1M in total across 1 funding round.
gIcare Pharma's investors include Sander van Deventer, Genesys Capital.
gIcare Pharma has raised $7.1M across 1 funding round. Most recently, it raised $7.1M Series A in September 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 6, 2011 | $7.1M Series A | Sander VAN Deventer, Genesys Capital | — | Announced |